BTIG Research Issues Pessimistic Forecast for Stryker (NYSE:SYK) Stock Price

Stryker (NYSE:SYK) had its target price decreased by investment analysts at BTIG Research from $316.00 to $304.00 in a report released on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the medical technology company’s stock. BTIG Research‘s target price suggests a potential downside of 2.29% from the company’s previous close.

A number of other research analysts have also commented on the stock. Argus set a $370.00 price objective on shares of Stryker in a research note on Thursday, July 9th. Raymond James Financial set a $370.00 target price on Stryker in a research report on Friday, July 31st. Citizens Jmp lowered their price target on Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research report on Monday, August 3rd. Sanford C. Bernstein reissued a “market perform” rating on shares of Stryker in a research note on Wednesday, October 7th. Finally, Evercore set a $350.00 price objective on Stryker in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $362.76.

Stryker Stock Performance

Shares of SYK opened at $311.12 on Friday. The firm has a 50-day moving average price of $293.56 and a 200 day moving average price of $324.86. The firm has a market capitalization of $119.34 billion, a PE ratio of 32.24, a P/E/G ratio of 1.96 and a beta of 0.78. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker has a 52-week low of $267.00 and a 52-week high of $389.33.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). The company had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.62 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The firm’s quarterly revenue was up 7.6% compared to the same quarter last year. During the same quarter last year, the firm posted $3.19 earnings per share. On average, sell-side analysts anticipate that Stryker will post 14.93 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Ronda Stryker sold 50,000 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the sale, the director owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This trade represents a 2.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 351,267 shares of company stock worth $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Stryker

Several hedge funds have recently modified their holdings of SYK. Gables Capital Management Inc. acquired a new position in shares of Stryker in the 2nd quarter valued at $25,000. Kilter Group LLC acquired a new stake in Stryker during the 2nd quarter worth about $25,000. Cornerstone Financial Management LLC raised its holdings in Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock worth $25,000 after buying an additional 31 shares during the period. Highland Investment Advisors LLC acquired a new stake in Stryker during the 2nd quarter worth about $25,000. Finally, Compass Financial Management LLC purchased a new stake in Stryker during the second quarter valued at about $27,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Third-quarter revenue increased approximately 7.6%–7.7% year over year to $6.52 billion, while adjusted EPS rose to $3.52 from $3.19 a year earlier. Stryker reports third quarter 2026 operating results
• Neutral Sentiment: Management is navigating manufacturing constraints in the vascular business and lingering operational effects from the cybersecurity incident disclosed in March. A new CEO is also taking over as the company reassesses its growth trajectory, making the 2027 starting point a key investor focus. Stryker’s Guidance Cut Rattles Investors
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 missed the roughly $3.55–$3.56 analyst consensus, and revenue of $6.52 billion fell short of the $6.62 billion estimate. The earnings and sales misses triggered a significant selloff. Stryker Q3 2026 earnings revenue and EPS miss
• Negative Sentiment: Stryker lowered its 2026 organic net sales growth forecast to 6.5%–7.0% from 8.3%–9.3%, while adjusted EPS guidance moved to $14.80–$14.90 from $14.95–$15.10. The larger sales reduction suggests demand, supply, or execution concerns beyond a one-quarter earnings miss. Stryker Slides After Lowering 2026 Outlook
• Negative Sentiment: Analysts subsequently cut their forecasts and price targets, reinforcing concerns about slower growth, margin pressure, and the company’s ability to regain momentum in 2027. Stryker Analysts Cut Their Forecasts

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.